Public Offering

NexMetals (TSXV:NEXM, Nasdaq:NEXM) launched a C$65 million public offering of Units (upsized from C$50M due to demand) at C$5.70 each. Each Unit contains one share and a warrant exercisable at C$8.00 for 24 months. Proceeds will prepay a contingent milestone for Selebi/Selkirk, advance Botswana development, and bolster working capital. Closing is expected around November 13, 2025. The offering includes a 15% over-allotment option and 6% agents’ fees, raising potential dilution concerns.

Tamboran Resources announced the pricing of its stock offering of 2,324,445 shares at $21.00 per share, expected to close on October 24, 2025, pending standard conditions. The offering, managed by RBC Capital Markets, Wells Fargo Securities, and BofA Securities, anticipates gross proceeds of approximately $48.8 million. Tamboran plans to use the funds for its development plan in the Beetaloo Basin, working capital, and general corporate purposes. The Beetaloo Basin represents a significant natural gas resource for Australia but faces risks including price fluctuations and regulatory hurdles.

Viridian Therapeutics (VRDN) announced the pricing of its public offering of 11,425,000 shares at $22.00 each, potentially generating $251.35 million in gross proceeds. Underwriters have an option to purchase additional shares. Closing is expected around October 23, 2025. Viridian will use the funds to support commercialization of veligrotug and VRDN-003 for Thyroid Eye Disease, ongoing research and development, and general corporate purposes. Jefferies, Leerink Partners, Evercore ISI, and Stifel are managing the offering.

Standard Lithium (SLI) plans a $120 million public offering of common shares, aiming to fund capital expenditures at its South West Arkansas and Franklin projects. Underwriters, led by Morgan Stanley and Evercore ISI, have a 30-day option to purchase up to 15% more shares. The offering is subject to market conditions and could dilute existing shareholders if completed. Proceeds will also support working capital and general corporate purposes.

EyePoint (EYPT) is undertaking a public offering to raise $150 million, priced on October 14, 2025. The offering includes 11,000,000 shares at $12.00 each and warrants for 1,500,000 shares at $11.999 each. Expected closing is around October 16, 2025. Underwriters have the option to purchase 1,875,000 more shares. Net proceeds will fund DURAVYU’s clinical development for wet AMD and DME, other pipeline projects, and general corporate expenses. The offering will be dilutive if warrants and the underwriter option are fully exercised.

Spyre Therapeutics (SYRE) announced the pricing of its public offering of 14,864,865 shares at $18.50 per share, projecting $275.0 million in gross proceeds. Underwriters have a 30-day option to purchase an additional 2,229,729 shares. The offering is expected to close around October 15, 2025, pending customary conditions. Funds will support research and development of antibody therapies for IBD and other immune-mediated conditions. Jefferies, TD Securities, Leerink Partners, and Stifel acted as joint book-running managers.

Hycroft Mining Holding Corporation (HYMC) announced a public offering of 23,076,924 Class A common stock shares at $6.50 per share, expecting $150 million in gross proceeds. These funds will be used to expand exploration and drilling at the Hycroft Mine in Nevada and to reduce debt. The offering, led by BMO Capital Markets, is expected to close on October 14, 2025. Hycroft focuses on developing its Nevada mine, one of the world’s largest precious metals deposits, while exploring high-grade silver systems.

AAR CORP. (NYSE: AIR) announced the pricing of a public offering of 3,000,000 shares of common stock at $83.00 per share. Underwriters have an option to purchase up to 450,000 additional shares. Net proceeds, estimated at $239 million (potentially $274.9 million with the option), will primarily repay debt under its revolving credit facility and for general corporate purposes, including potential acquisitions. Goldman Sachs, Jefferies, and RBC Capital Markets are the joint lead book-running managers. The offering is expected to close around October 2, 2025.

bioAffinity Technologies announced the completion of a public offering, generating $4.8 million in gross proceeds. The offering included shares of common stock and pre-funded warrants. WallachBeth Capital, LLC served as the placement agent. bioAffinity focuses on non-invasive cancer diagnostics, including CyPath® Lung, a Laboratory Developed Test for early lung cancer detection. The company addresses the growing precision diagnostics market with a focus on improving patient outcomes through early diagnosis. The announcement contains forward-looking statements subject to risks detailed in SEC filings.

Soligenix, Inc. (SNGX) announced a public offering of 5,555,560 shares of common stock (or equivalents) with warrants at $1.35 per share/warrant. The warrants are immediately exercisable at $1.35, expiring in five years. Existing warrants for 1,162,064 shares will be amended to the same price and expiration. The offering, expected to close around September 29, 2025, aims to raise $7.5 million, which will fund R&D, commercialization, and general corporate needs. A.G.P./Alliance Global Partners is the sole placement agent. This offering is under an effective SEC registration statement.